ABSTRACT
This chapter describes trade name, classification, approved indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, relative contraindications, and clinically significant drug interactions of Paroxetine. For most hospitalized patients, two to three weeks of trifluoperazine pharmacotherapy at the optimal dosage will be adequate before initiating a gradual reduction of the dosage to a maintenance dosage. Safety and efficacy of trifluoperazine pharmacotherapy for women who are breast-feeding and their neonates and infants have not been established. There is evidence that trifluoperazine is excreted in breast milk. Two to three weeks of trifluoperazine pharmacotherapy are usually required for optimal therapeutic benefit. Prescribe trifluoperazine pharmacotherapy cautiously to patients who have cardiovascular dysfunction. Trifluoperazine may decrease the neuronal uptake of guanethidine and, thus, decrease its antihypertensive action. Adverse drug reactions have been infrequently associated with trifluoperazine pharmacotherapy.
